Zymeworks (ZYME) Total Current Liabilities (2021 - 2026)
Zymeworks (ZYME) posted Total Current Liabilities of $35.6 million for Q1 2026, down 15.76% sequentially from $42.3 million in Q4 2025, and down 45.24% YoY from $65.1 million in Q1 2025.
Analysis
Zymeworks (ZYME) Total Current Liabilities (2021 - 2026) Analysis & Trends
Zymeworks has reported Total Current Liabilities for 6 years, with the latest figure at $35.6 million in Q1 2026.
- Quarterly Total Current Liabilities fell 45.24% year-over-year to $35.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.6 million (down 45.24% YoY) and the FY2025 annual result came in at $42.3 million, down 52.07% from the prior year.
- Total Current Liabilities slipped to $35.6 million in Q1 2026 per ZYME's latest filing, from $42.3 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $95.6 million in Q4 2022 and troughed at $35.6 million in Q1 2026.
- A 5-year average of $63.3 million and a median of $57.7 million in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 58.34% in 2024, then tumbled 52.07% in 2025.
- Over 5 years, Total Current Liabilities stood at $95.6 million in 2022, then slumped by 41.69% to $55.8 million in 2023, then jumped by 58.34% to $88.3 million in 2024, then slumped by 52.07% to $42.3 million in 2025, then fell by 15.76% to $35.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $35.6 million, $42.3 million, and $42.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | 47.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47.24 Mn |
| Mar 31, 2026 | 35.65 Mn |
| Dec 31, 2025 | 42.32 Mn |
| Sep 30, 2025 | 42.04 Mn |
| Jun 30, 2025 | 38.50 Mn |
| Mar 31, 2025 | 65.10 Mn |
| Dec 31, 2024 | 88.29 Mn |
| Sep 30, 2024 | 83.91 Mn |
| Jun 30, 2024 | 54.71 Mn |
| Mar 31, 2024 | 56.89 Mn |
| Dec 31, 2023 | 55.76 Mn |
| Sep 30, 2023 | 72.85 Mn |
| Jun 30, 2023 | 93.55 Mn |
| Mar 31, 2023 | 67.32 Mn |
| Dec 31, 2022 | 95.63 Mn |
| Sep 30, 2022 | 57.71 Mn |
| Dec 31, 2021 | 71.85 Mn |